(¿Â¶óÀÎ)´ëÇÑÁ¾¾ç³»°úÇÐȸ 1/12 ºÐ±âÁý´ãȸ : 2023-01-12±³À°ÀÏÀÚ : 2023-01-12
±³À°Àå¼Ò : ¿Â¶óÀÎ
±³À°ÁÖÁ¦ :
(¿Â¶óÀÎ)´ëÇÑÁ¾¾ç³»°úÇÐȸ 1/12 ºÐ±âÁý´ãȸÁÖÃÖ±â°ü : ´ëÇÑÁ¾¾ç³»°úÇÐȸ(17.5 ¸íĪº¯°æ Çѱ¹ÀÓ»ó¾ÏÇÐȸ)
´ã´çÀÚ : ±è¿¹Áö
¿¬¶ôó : 070-4367-2707
À̸ÞÀÏ :
meetings@ksmo.or.kr ±³À°Á¾·ù : ³»°ú
Âü¼®¿¹»óÀοø : 200¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
¼¿ïƯº°½Ã±³À°½Ã°£ : 3 ½Ã°£ 0ºÐ
¼¼ºÎ¼ö°·á : 20,000¿ø
ºñ°í ´ëÇÑÁ¾¾ç³»°úÇÐȸ ȸ¿ø ¹«·á / ºñȸ¿ø 20000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 01-12 ¿Â¶óÀÎ 18:00~18:45 MET, RET inhibitors in NSCLC À°Á¤È¯(¼¿ï´ëº´¿ø Á¾¾ç³»°ú)
±³À°½Ã°£ 01-12 ¿Â¶óÀÎ 18:45~19:30 Lazertinib as first line treatment option in patients with EGFR mutant NSCLC ÀÌÁöÀ±(¿¬¼¼¾Ïº´¿ø Æó¾Ï¼¾ÅÍ)
±³À°½Ã°£ 01-12 ¿Â¶óÀÎ 19:30~20:15 Best treatment option as 1st line in advanced ESCC À̱â»Ý(¿¬¼¼¾Ïº´¿ø Á¾¾ç³»°ú)
±³À°½Ã°£ 01-12 ¿Â¶óÀÎ 20:15~21:00 How can we maintain nutritional support in patients with advanced ESCC? ½Åö¹Î(ºÐ´ç¼¿ï´ëº´¿ø ¼Òȱ⳻°ú)